The estimated Net Worth of Joseph L Turner is at least $230 Thousand dollars as of 13 March 2013. Mr. Turner owns over 10,000 units of Miragen Therapeutics Inc stock worth over $230,100 and over the last 14 years he sold MGEN stock worth over $0. In addition, he makes $0 as Independent Director at Miragen Therapeutics Inc.
Joseph has made over 1 trades of the Miragen Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of MGEN stock worth $20,100 on 13 March 2013.
The largest trade he's ever made was buying 10,000 units of Miragen Therapeutics Inc stock on 13 March 2013 worth over $20,100. On average, Joseph trades about 526 units every 0 days since 2010. As of 13 March 2013 he still owns at least 10,000 units of Miragen Therapeutics Inc stock.
You can see the complete history of Mr. Turner stock trades at the bottom of the page.
Joseph L. Turner Jr. serves as Independent Director of the Company. Mr. Turner has served as a member of our Board since February 2017. Mr. Turner currently serves on the board of directors of Rainier Therapeutics, Inc. Prior to joining our Board, Mr. Turner served on the boards of directors and was the chair of the audit committees of Corcept Therapeutics, Inc., a publicly-traded pharmaceutical company, from 2012 to May 2016, Kythera Biopharmaceuticals, Inc., a publicly-traded pharmaceutical company, from 2008 until Kythera’s acquisition by Allergan Inc. October 2015, and Sophiris Bio, a publicly-traded pharmaceutical company from 2013 to May 2016. From July 2010 until its acquisition by Grupo Ferrer Internacional, S.A. in June 2016, Mr. Turner served on the board of directors and as a chair of the audit committee of Alexza Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. In 2012, Mr. Turner served on the board of directors and as chair of the audit committee of Allos Therapeutics, Inc., a publicly-traded pharmaceutical company, until its acquisition by Spectrum Pharmaceuticals Inc. in September 2012. From 2010 through 2012, he served on the board of directors and as a member of the audit committee of QLT Inc., a publicly-traded biotechnology company. In 2008, Mr. Turner served as a director and member of the audit committee of SGX Pharmaceuticals Inc., a publicly-traded pharmaceutical company. Mr. Turner served as chief financial officer at Myogen, Inc., a publicly-traded biopharmaceutical company, from 1999 until it was acquired by Gilead Sciences in 2006. Previously, Mr. Turner was the chief financial officer at Centaur Pharmaceuticals, Inc. and served as chief financial officer and vice president, finance and administration at Cortech, Inc. Since 2009, Mr. Turner has an M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in molecular biology from the University of Colorado, and a B.A. in chemistry from Swarthmore College.
Joseph Turner is 68, he's been the Independent Director of Miragen Therapeutics Inc since 2017. There are no older and 8 younger executives at Miragen Therapeutics Inc.
Joseph's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Over the last 8 years, insiders at Miragen Therapeutics Inc have traded over $636,110 worth of Miragen Therapeutics Inc stock and bought 1,041,411 units worth $5,368,137 . The most active insiders traders include Bennett S Lebow, Bruce Booth, and Paul D Rubin. On average, Miragen Therapeutics Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,345,685. The most recent stock trade was executed by Global Master Fund Lp Logos on 9 November 2020, trading 476,667 units of MGEN stock currently worth $2,268,935.
Miragen Therapeutics Inc executives and other stock owners filed with the SEC include: